The present invention relates to compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as Autotaxin (ATX) inhibitors.
The present invention relates to compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as Autotaxin (ATX) inhibitors.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
39 - Transport, packaging, storage and travel services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals; Medicine; Vaccines; Medicinal healthcare preparations. Medical apparatus and instruments; Dental apparatus and instruments; Dental apparatus and instruments; Sphygmotensiometers; Thermometers for medical purposes; Walking sticks for medical purposes; Oral irrigators for use in dentistry; Electrical oral irrigators for use by dentists; Masks for use by medical personnel; Sanitary masks for medical purposes; Surgical masks; Hygienic masks for medical purposes; Respiratory masks for medical purposes; High filter surgical masks; Respiratory masks for artificial respiration; Protective breathing masks made of non-woven materials for surgical applications; Protective breathing masks for surgical applications; Surgical breathing masks; Protective breathing masks for artificial respiration; Respiratory masks for medical purposes; Face masks for medical use; Surgical masks; Face masks for medical use for anti bacterial protection; Face masks for surgical use for anti bacterial protection. Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: pharmaceuticals, medicines, Vaccines, Medicinal health care preparations, Medical apparatus and instruments; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Dental instruments, Dental apparatus and instruments, Sphygmomanometers, Thermometers for medical purposes; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Canes for medical purposes, Oral irrigators for use in dentistry, Electrical oral irrigators for use by dentists, Masks for use by medical personnel, Sanitary masks for medical use, Surgical masks, Hygienic masks for medical purposes; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Respiratory masks for medical purposes, High filtration surgical masks, Respiratory masks for artificial respiration; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Protective breathing masks made of non-woven materials for surgical applications, Protective breathing masks for surgical applications; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Surgical respiratory masks, Protective breathing masks for artificial respiration, respiratory masks for medical purposes; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Face masks for medical purposes, Face masks for surgical purposes, Anti-bacterial protective face masks for medical purposes and Face masks for surgical use for anti bacterial protection; Merchandising; Advertising, marketing and promotional services. Distribution services, Transport and Storage Relating to the following goods: Pharmaceuticals, Medicines, Vaccinations, Medicinal healthcare preparations, Medical apparatus and instruments; Distribution services, Transport and Storage Relating to the following goods: Odontological apparatus and instruments, dental apparatus and dental instruments, sphygmotensiometers, Thermometers for medical purposes; Distribution services, Transport and Storage Relating to the following goods: Walking sticks for medical purposes, oral irrigators for use in dentistry, electrical oral irrigators for use by dentists; Distribution services, Transport and Storage Relating to the following goods: Masks for use by medical personnel, sanitary masks for medical use, surgical masks, sanitary masks for medical purposes, respiratory masks for medical purposes, high filter surgical masks, respiratory masks for artificial respiration; Distribution services, Transport and Storage Relating to the following goods: Protective breathing masks made of non-woven materials for surgical applications, protective breathing masks for surgical applications, surgical breathing masks; Distribution services, Transport and Storage Relating to the following goods: Protective breathing masks for artificial respiration, respiratory masks for medical purposes, face masks for medical use, surgical masks, face masks for medical use for anti-bacterial protection, face masks for surgical use for anti-bacterial protection; Storage of pharmaceuticals. Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical products development; Research on the subject of pharmaceuticals; Pharmaceutical research and development; Scientific research.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
39 - Transport, packaging, storage and travel services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals; Medicine; Vaccines; Medicinal healthcare preparations. Medical apparatus and instruments; Dental apparatus and instruments; Dental apparatus and instruments; Sphygmotensiometers; Thermometers for medical purposes; Walking sticks for medical purposes; Oral irrigators for use in dentistry; Electrical oral irrigators for use by dentists; Masks for use by medical personnel; Sanitary masks for medical purposes; Surgical masks; Hygienic masks for medical purposes; Respiratory masks for medical purposes; High filter surgical masks; Respiratory masks for artificial respiration; Protective breathing masks made of non-woven materials for surgical applications; Protective breathing masks for surgical applications; Surgical breathing masks; Protective breathing masks for artificial respiration; Respiratory masks for medical purposes; Face masks for medical use; Surgical masks; Face masks for medical use for anti bacterial protection; Face masks for surgical use for anti bacterial protection. Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: pharmaceuticals, medicines, Vaccines, Medicinal health care preparations, Medical apparatus and instruments; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Dental instruments, Dental apparatus and instruments, Sphygmomanometers, Thermometers for medical purposes; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Canes for medical purposes, Oral irrigators for use in dentistry, Electrical oral irrigators for use by dentists, Masks for use by medical personnel; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Sanitary masks for medical use, Surgical masks, Hygienic masks for medical purposes, Respiratory masks for medical purposes; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: High filtration surgical masks, Respiratory masks for artificial respiration, Protective breathing masks made of non-woven materials for surgical applications, Protective breathing masks for surgical applications, Surgical respiratory masks, Protective breathing masks for artificial respiration; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: respiratory masks for medical purposes, Face masks for medical purposes, Face masks for surgical purposes, Anti-bacterial protective face masks for medical purposes and Face masks for surgical use for anti bacterial protection; Merchandising; Advertising, marketing and promotional services. Distribution services, Transport and Storage Relating to the following goods: Pharmaceuticals, Medicines, Vaccinations, Medicinal healthcare preparations, Medical apparatus and instruments, Dentistry apparatus and instruments, dental apparatus and instruments; Distribution services, Transport and Storage Relating to the following goods: Sphygmomanometers, Thermometers for medical purposes, Walking canes for medical purposes, Oral irrigators for use in dentistry, electric oral irrigators for use in dentistry, masks for use by medical personnel, sanitary masks for medical purposes, Surgical masks; Distribution services, Transport and Storage Relating to the following goods: Hygiene masks for medical purposes, Breathing masks for medical purposes, High filter surgical masks, respiratory masks for artificial respiration; Distribution services, Transport and Storage Relating to the following goods: Protective breathing masks made of non-woven materials for surgical applications, protective breathing masks for surgical applications; Distribution services, Transport and Storage Relating to the following goods: Surgical breathing masks, protective breathing masks for artificial respiration, Breathing masks for medical purposes, Face masks for medical purposes; Distribution services, Transport and Storage Relating to the following goods: Surgical masks, face masks for surgical use for anti-bacterial protection for medical purposes, Anti-bacterial protective face masks for medical purposes, face masks for surgical use for anti-bacterial protection; Storage of pharmaceuticals. Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical products development; Research on the subject of pharmaceuticals; Pharmaceutical research and development; Scientific research.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
39 - Transport, packaging, storage and travel services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals; Medicine; Vaccines; Medicinal healthcare preparations. Medical apparatus and instruments; Dental apparatus and instruments; Dental apparatus and instruments; Sphygmotensiometers; Thermometers for medical purposes; Walking sticks for medical purposes; Oral irrigators for use in dentistry; Electrical oral irrigators for use by dentists; Masks for use by medical personnel; Sanitary masks for medical purposes; Surgical masks; Hygienic masks for medical purposes; Respiratory masks for medical purposes; High filter surgical masks; Respiratory masks for artificial respiration; Protective breathing masks made of non-woven materials for surgical applications; Protective breathing masks for surgical applications; Surgical breathing masks; Protective breathing masks for artificial respiration; Respiratory masks for medical purposes; Face masks for medical use; Surgical masks; Face masks for medical use for anti bacterial protection; Face masks for surgical use for anti bacterial protection. Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: pharmaceuticals, medicines, Vaccines, Medicinal health care preparations, Medical apparatus and instruments; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Dental instruments, Dental apparatus and instruments, Sphygmomanometers, Thermometers for medical purposes, Canes for medical purposes, Oral irrigators for use in dentistry, Electrical oral irrigators for use by dentists, Masks for use by medical personnel; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Sanitary masks for medical use, Surgical masks, Hygienic masks for medical purposes, Respiratory masks for medical purposes, High filtration surgical masks, Respiratory masks for artificial respiration; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Protective breathing masks made of non-woven materials for surgical applications; Protective breathing masks for surgical applications; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Surgical respiratory masks, Protective breathing masks for artificial respiration, respiratory masks for medical purposes; Retail services, Distribution wholesale and Sale via global networks in relation to the following goods: Face masks for medical purposes, Face masks for surgical purposes, Anti-bacterial protective face masks for medical purposes and Face masks for surgical use for anti bacterial protection; Merchandising; Advertising, marketing and promotional services. Distribution services, Transport and Storage Relating to the following goods: Pharmaceuticals, Medicines, Vaccinations, Medicinal healthcare preparations, Medical apparatus and instruments, Dental apparatus and instruments; Distribution services, Transport and Storage Relating to the following goods: Dental apparatus and instruments, sphygmotensiometers, Thermometers for medical purposes, Walking canes for medical purposes, Oral irrigators for use in dentistry; Distribution services, Transport and Storage Relating to the following goods: Electrical oral irrigators for use by dentists, masks for use by medical personnel, sanitary masks for medical purposes, Surgical masks, sanitary masks for medical purposes; Distribution services, Transport and Storage Relating to the following goods: Breathing masks for medical purposes, High filter surgical masks, respiratory masks for artificial respiration; Distribution services, Transport and Storage Relating to the following goods: Protective breathing masks made of non-woven materials for surgical applications, protective breathing masks for surgical applications; Distribution services, Transport and Storage Relating to the following goods: Surgical breathing masks, protective breathing masks for artificial respiration, Breathing masks for medical purposes; Distribution services, Transport and Storage Relating to the following goods: Face masks for medical purposes, Surgical masks, face masks for surgical use for anti-bacterial protection for medical purposes, Anti-bacterial protective face masks for medical purposes, face masks for surgical use for anti-bacterial protection; Storage of pharmaceuticals. Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical products development; Research on the subject of pharmaceuticals; Pharmaceutical research and development; Scientific research.
The present invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof for the treatment or management of muscle spasms in musculoskeletal diseases and/or painful physical symptoms in neurological diseases. In particular, the invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof and one or more pharmaceutically acceptable excipients.
The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators and use of these novel inhibitor compounds in the treatment of disease or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Present invention relates to orodispersible formulation of suitable hypolipidemic agent. Preferably, the present invention discloses novel orodispersible formulation of the compound of formula (I), or its pharmaceutically acceptable salts and preparation of such stable pharmaceutical formulations.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to parenteral compositions comprising methylene blue, water and one or more pH regulating agents. The present invention also relates to processes for preparing such compositions.
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
The invention relates to enantiomerically pure desglymidodrine and process for preparation thereof. In particular, the invention relates to enantiomerically pure desglymidodrine or a pharmaceutically acceptable salt, solvate or a hydrate, thereof. More particularly, the invention relates to individual enantiomers of desglymidodrine in chirally pure form or a pharmaceutically acceptable salt, solvate or a hydrate, thereof. The invention also relates to the process for their preparation, pharmaceutical compositions comprising the same and use thereof in eliciting vasopressor or antihypotensive effect in mammals.
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
C07C 213/10 - SeparationPurificationStabilisationUse of additives
C07C 217/70 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
The present invention relates to compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as Autotaxin (ATX) inhibitors.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
Present invention relates to compounds of general formula (I), their tautomeric forms, stereoisomers, pharmaceutically acceptable salts and pharmaceutical composition containing them. Invention also relates to process for the preparation of compounds of general formula (I) and intermediates thereof. Compounds of present invention can be useful in treating diseases such as hyperlipidemia and other disorders related to hyperlipidemia. Compounds of present invention also have a beneficial effect on lowering cholesterol.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 477/00 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycinsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-inflammatories; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; Pharmaceutical preparations for the treatment and prevention of hematalogic disorders and for use in tissue and organ transplantation; Pharmaceutical preparations for the treatment and prevention of eye diseases and conditions; Pharmaceutical preparations for the treatment and prevention of heart rhythm disorders; Pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of kidney diseases; Pharmaceutical preparations for the treatment and prevention of hypertension; Pharmaceutical preparations for the treatment and prevention of skin disorders; Pharmaceutical preparations for the treatment and prevention of cancer and tumors; Pharmaceutical preparations for the treatment and prevention of allergies; Pharmaceutical preparations for the treatment and prevention of bone diseases; Pharmaceutical preparations for the treatment and prevention of respiratory diseases and asthma; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-inflammatories; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; Pharmaceutical preparations for the treatment and prevention of hematalogic disorders and for use in tissue and organ transplantation; Pharmaceutical preparations for the treatment and prevention of eye diseases and conditions; Pharmaceutical preparations for the treatment and prevention of heart rhythm disorders; Pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of kidney diseases; Pharmaceutical preparations for the treatment and prevention of hypertension; Pharmaceutical preparations for the treatment and prevention of skin disorders; Pharmaceutical preparations for the treatment and prevention of cancer and tumors; Pharmaceutical preparations for the treatment and prevention of allergies; Pharmaceutical preparations for the treatment and prevention of bone diseases; Pharmaceutical preparations for the treatment and prevention of respiratory diseases and asthma; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use
17.
ANTI-SARS-COV-2 MONOCLONAL ANTIBODIES AND COCKTAIL THEREOF
The present invention provides monoclonal antibody capable of binding and neutralizing virus of coronavirus family, preferably SARS-CoV-2. It also provides a cocktail of at least two monoclonal antibodies capable of binding and neutralizing virus of coronavirus family, preferably SARS-CoV-2. According to the present invention, the monoclonal antibody or cocktail of at least two monoclonal antibodies can bind and neutralize coronavirus including, but not limited to, SARS-CoV-2, MERS CoV and SARS-CoV. In one aspect, the present invention provides pharmaceutical composition of monoclonal antibody or cocktail of atleast two monoclonal antibody capable of binding and neutralizing virus of coronavirus family, preferably SARS-CoV-2. In another aspect, present invention provides process of preparing monoclonal antibody or cocktail of atleast two monoclonal antibody capable of binding and neutralizing virus of coronavirus family, preferably SARS-CoV-2.
The present invention relates to novel compounds of general formula (I), their tautomeric forms & deuterated forms, their pharmaceutically acceptable salts, prodrugs and their pharmaceutically acceptable salts, their polymorphs, pre-mixtures with excipients and polymers, and pharmaceutical compositions containing them. The present invention also relates to a process for preparing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compositions containing them.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diabetes only, not for intravenous administration or administration by infusion; none of the foregoing for treatment, or any associated treatment, of blood disorders or immunological diseases
20.
PARENTERAL SOLUTIONS OF SELECTIVE CYCLOOXYGENASE-2 (COX-2) INHIBITOR AND USE THEROF FOR TREATING PAIN / ARTHRITIS
The present invention relates to parenteral solutions comprising selective cyclooxygenase-2 (COX-2) inhibitor. The present invention also relates to processes for preparing such parenteral solutions. The present invention also relates to a method of treating pain or arthritis comprising administering such parenteral solution to a human being in need thereof through a parenteral route, viz., intravenous route, subcutaneous route or intramuscular route.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of papain-like protease (PLpro) modulators. The present invention thus relates to novel papain-like protease (PLpro) modulators and their use in the treatment of diseases or conditions in which SARS-CoV, SARS-CoV2 is implicated like severe acute respiratory syndrome (SARS), Middle east respiratory syndrome (MERS), Spanish flu, COVID19 (Coronavirus disease 2019), hepatitis C virus, chikungunya virus, influenza A virus, herpes simplex virus type 1 and Japanese encephalitis virus. Formula (I)
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 11/00 - Drugs for disorders of the respiratory system
22.
INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE FOR MANAGEMENT OF METABOLIC DISORDER
The present invention relates to novel modulators of low molecular weight protein tyrosine phosphatases and their use for the treatment of diseases or conditions mediated by LMPTP. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, their safe pre-mixtures with polymers such as HPMC, HPMC-AS, Copovidone and methods for using such compounds, and pharmaceutical compositions containing them.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
39 - Transport, packaging, storage and travel services
Goods & Services
Medical apparatus and instruments; dental apparatus and
instruments; dental apparatus and instruments;
Sphygmomanometers; thermometers for medical use; canes for
medical use; oral irrigators for use in dentistry; electric
oral irrigators for use by dentists; masks for medical
personnel; sanitary masks for medical use; surgical masks;
sanitary masks for medical use; respiratory masks for
medical use; high filtration surgical masks; respiratory
masks for artificial respiration; protective respiratory
masks made from non-woven materials for surgical
applications; protective respiratory masks for surgical
applications; surgical respiratory masks; protective
respiratory masks for artificial respiration; respiratory
masks for medical use; face masks for medical use; face
masks for surgical use; face masks for antibacterial
protection for medical use; face masks for antibacterial
protection for surgical use. Retail services or retail services in stores, wholesale and
retail services via global computer networks for medical
apparatus and instruments, dental apparatus and instruments,
dental apparatus and instruments, sphygmotensiometers,
thermometers for medical use, canes for medical use, oral
irrigators for use in dentistry, electric oral irrigators
for use by dentists, scales, walking sticks, rotating heads
for foot files for removing hardened skin, masks for medical
personnel, sanitary masks for medical use, surgical masks,
sanitary masks for medical use, respiratory masks for
medical use, high filtration surgical masks, respiratory
masks for artificial respiration, protective respiratory
masks made from non-woven materials for surgical
applications, protective respiratory masks for surgical
applications, surgical respiratory masks, protective
respiratory masks for artificial respiration, respiratory
masks for medical use, face masks for medical use, face
masks for surgical use, face masks for antibacterial
protection for medical use, face masks for antibacterial
protection for surgical use. Distribution services; transport; warehousing services for
medical apparatus and instruments, dental apparatus and
instruments, dental apparatus and instruments,
sphygmotensiometers, thermometers for medical use, canes for
medical use, oral irrigators for use in dentistry, electric
oral irrigators for use by dentists, scales, walking sticks,
rotating heads for foot files for removing hardened skin,
masks for medical personnel, sanitary masks for medical use,
surgical masks, sanitary masks for medical use, respiratory
masks for medical use, high filtration surgical masks,
respiratory masks for artificial respiration, protective
respiratory masks made from non-woven materials for surgical
applications, protective respiratory masks for surgical
applications, surgical respiratory masks, protective
respiratory masks for artificial respiration, respiratory
masks for medical use, face masks for medical use, face
masks for surgical use, face masks for antibacterial
protection for medical use, face masks for antibacterial
protection for surgical use.
The present invention relates to novel heterocyclic compounds of general formula (I) and their pharmaceutically acceptable salts, enantiomers and their diastereomers that are autotaxin (ATX) inhibitors. Compounds of general formula (I), their pharmaceutically acceptable salts and pharmaceutical composition are useful for the treatment and prophylaxis of conditions or a disorder caused by autotaxin (ATX) activation or increased concentration of lysophosphatidic acid (LPA).
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
Present invention relates to development of compound of formula (Ia) for treatment of inflammatory bowel diseases. Invention also relates to pharmaceutical composition comprising therapeutically effective compound of formula (Ia) for treatment of inflammatory bowel diseases.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
The present invention relates to a composition of PEGylated interferon alpha-2b for use in treatment of SARS-CoV-2 infection and its related clinical manifestations. The said composition according to the present invention is a pharmaceutical composition. Current invention also provides dose and dose regimen of PEGylated interferon alpha-2b for use in treatment of severe acute respiratory syndrome related coronavirus, preferably SARS-CoV-2 and its related clinical manifestations. The invention also discloses a method of treatment of severe acute respiratory syndrome related coronavirus, preferably SARS-CoV-2 and its related clinical manifestations using the composition of PEGylated interferon alpha-2b as disclosed herein. Further disclosed is the use of the composition of PEGylated interferon alpha-2b as disclosed herein below for the treatment of severe acute respiratory syndrome related coronavirus, preferably SARS-CoV-2 and its related clinical manifestations.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Present invention relates to development of prolyl hydroxylase inhibitor for treatment of Psoriasis and skin inflammatory diseases. Specifically, invention relates to development of compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases. Invention also relates to pharmaceutical composition comprising compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
The present invention relates to Fc variant protein and preparation thereof. Said Fc variant has altered binding affinity towards FcRn. Fc variant prepared according to the current invention can be used for making FcRn antagonist composition or can be used for making an Fc variant containing drug or molecule with altered effector function.
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
39 - Transport, packaging, storage and travel services
Goods & Services
Pharmaceutical products; medicines; medicinal preparations
for health care. Retail services in stores, wholesale services and retail
services via global computer networks for pharmaceutical
products, medicines and medical preparations for health
care; commercial promotion services; promotional,
marketing and advertising services. Distribution services; transport; warehousing services for
pharmaceutical products, medicines and medical preparations
for health care; storage of pharmaceutical products.
30.
STABLE AQUEOUS PARENTERAL SOLUTIONS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)
The present invention relates to stable aqueous parenteral solutions comprising nonsteroidal anti-inflammatory drugs (NSAIDs) and polyvinylpyrrolidone. It also relates to a prefilled-syringe and a kit comprising such parenteral solutions. It also relates to a method of treating migraine and various kinds of body pain comprising administering such parenteral solution through a parenteral route.
Present invention describes synergistic composition comprising compound of formula (I) and at least one additional therapeutic agents such as ezetimibe, eicosapentaenoic acid, nicotinic acid derivatives and bempedoic acid derivatives, salt thereof. Invention also describes use of synergistic composition for the treatment or prevention of a disease or condition such as metabolic disorder and cardiovascular diseases.
The current invention provides a DNA construct comprising S gene or S1 gene region of 2019-nCoV spike-S protein. The DNA construct of the present invention comprises DNA plasmid vector carrying S gene or S1 gene region of 2019-nCoV spike-S protein. The vector may further comprise a gene encoding IgE signal peptide or a gene encoding t-PA signal peptide. The DNA construct according to the present invention is further used in the preparation of an immunogenic composition or a vaccine for treating or preventing corona virus or its related diseases.
The present invention relates to stable aqueous parenteral solutions comprising desglymidodrine and one or more pharmaceutically acceptable excipients comprising one or more pH adjusting agents, wherein pH of the solution is from about 4 to about 8 and the invention also relates to processes for preparing such aqueous parenteral solutions for treating hepatorenal syndrome comprising administering such aqueous parenteral solutions through a parenteral route.
The present invention generally relates to a pharmaceutical composition of suitable HIF prolyl hydroxylase inhibitors. Preferably, the present invention discloses novel formulations of the compound of formula (Ia), or pharmaceutically acceptable salts of compounds of formula (Ia). More particularly the present invention relates to the pharmaceutical composition of compounds of formula (Ia) comprising compounds of formula (Ia) or its pharmaceutically acceptable salts.
C07D 215/58 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
The present invention relates to novel pharmaceutically acceptable salts of formula (Ia). The invention is also related to process for the preparation of the said novel salts and pharmaceutical composition of the same. Compounds of the present invention are prolyl hydroxylase inhibitors and are suitable for the treatment of anemia.
C07D 215/00 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
C07D 215/58 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1β activity is implicated.
A01N 47/36 - Ureas or thioureas containing the groups N—CO—N or N—CS—N containing the group N—CO—N directly attached to at least one heterocyclic ringThio-analogues thereof
C07D 213/34 - Sulfur atoms to which a second hetero atom is attached
γγRs to minimize its ADCC activity. The present invention provide an antibody that comprises an amino acid sequence to minimise its CDC activity. The antibody according to the present invention has higher FcRn binding affinity and therefore the antibody according to the present invention may have long circulating half-life in the body of the patient and it can be given at a reduced dosing frequency. The antibody according to the present invention can further be used in the preparation of a drug for treating diseases through inhibition of alternative complement pathway.
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation The present invention is directed towards compounds which can be useful in treating diseases such as Hyperlipidemia and also have a beneficial effect on lowering cholesterol.
C07D 211/10 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators and use of these novel inhibitor compounds in the treatment of disease or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin- 18 (IL-18) is implicated.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
40.
MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF RIOCIGUAT
The present invention relates to modified release pharmaceutical compositions of riociguat or a pharmaceutically acceptable salt thereof. In particular, the compositions of the invention are stable, possess formulation characteristics and also provide extended therapeutically effective plasma levels over twenty four hour time period. The invention also relates to processes of preparing such compositions.
39 - Transport, packaging, storage and travel services
Goods & Services
Medical apparatus and instruments; Dental apparatus and instruments; Dental apparatus and instruments; Tensiometers; Thermometers for medical purposes; Walking sticks for medical purposes; Oral irrigators for use in dentistry; Electrical oral irrigators for use by dentists; Masks for use by medical personnel; Sanitary masks for medical purposes; Surgical masks; Hygienic masks for medical purposes; Respiratory masks for medical purposes; High filter surgical masks; Respiratory masks for artificial respiration; Protective breathing masks made of non-woven materials for surgical applications; Protective breathing masks for surgical applications; Surgical breathing masks; Protective breathing masks for artificial respiration; Respiratory masks for medical purposes; Face masks for medical use; Surgical masks; Face masks for medical use for anti bacterial protection; Face masks for surgical use for anti bacterial protection. Retailing and commercial retailing, Wholesaling, retailing via global computer networks, in relation the following goods, apparatus and Medical instrumentation, Dental instruments, Dental apparatus and instruments, Sphygmomanometers, Thermometers for medical purposes, Canes for medical purposes, Oral irrigators for use in dentistry, Electrical oral irrigators for use by dentists, scales, canes, Foot file roller heads for removing hardened skin, Masks for use by medical personnel, Sanitary masks for medical use, Surgical masks, Hygienic masks for medical purposes, Respiratory masks for medical purposes, High filtration surgical masks, Respiratory masks for artificial respiration, Protective breathing masks made of non-woven materials for surgical applications, Protective breathing masks for surgical applications, Surgical respiratory masks, Protective breathing masks for artificial respiration, Respiratory masks for medical purposes, Face masks for medical purposes, Face masks for surgical purposes, Anti-bacterial protective face masks for medical purposes, Face masks for surgical use for anti bacterial protection. Distribution services; Transport; Storage of medical apparatus and instruments, odontological apparatus and instruments, dental apparatus and instruments, tensiometers, thermometers for medical purposes, walking sticks for medical purposes, oral irrigators for use in dentistry, electric oral irrigators for use by dentists, scales, walking sticks, foot file roller heads for removing hardened skin, masks for use by medical personnel, sanitary masks for medical purposes, surgical masks, hygienic masks for medical purposes, respiratory masks for medical purposes, high filtration surgical masks, respiratory masks for artificial respiration, protective breathing masks made of non-woven materials for surgical applications, protective breathing masks for surgical applications, surgical breathing masks, protective breathing masks for artificial respiration, respiratory masks for medical purposes, face masks for medical purposes, face masks for surgical purposes, anti-bacterial protective face masks for medical purposes, face masks for surgical use for anti bacterial protection.
42.
PHARMACEUTICAL FORMULATION OF ANTI-HER2 ANTIBODY AND PREPARATION THEREOF
The present invention provides novel stable pharmaceutical formulation of anti-HER2 antibody, preferably pertuzumab formulated in presence of arginine containing buffer(s), wherein the arginine containing buffer is selected from arginine-succinate buffer, arginine-phosphate buffer arginine-acetate buffer, arginine-aspartate buffer, arginine-citrate buffer and suitable combination thereof. The pharmaceutical formulation according to the present invention comprises pertuzumab and about 50 to about 500 mM of buffer(s) with one or more suitable excipients. Further, the present invention also provides the pharmaceutical formulation comprising therapeutically effective amount of anti-HER2 antibody, preferably pertuzumab antibody, buffer and amino acid(s) with one or more suitable excipient(s). In one of the aspects, the present invention provides liquid or lyophilized or frozen pharmaceutical formulation of anti-HER2 antibody preferably, pertuzumab. Other aspect of the present invention includes method of making pharmaceutical formulation of anti-HER2 antibody, preferably pertuzumab.
The present invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof for the treatment or management of muscle spasms in musculoskeletal diseases and/or painful physical symptoms in neurological diseases. In particular, the invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof and one or more pharmaceutically acceptable excipients.
The present invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof for the treatment or management of muscle spasms in musculoskeletal diseases and/or painful physical symptoms in neurological diseases. In particular, the invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof and one or more pharmaceutically acceptable excipients.
The invention relates to stable, aqueous, parenteral solutions comprising one or more nonsteroidal anti-inflammatory drugs (NSAIDs) and polyvinylpyrrolidone. The present invention also relates to processes for preparing such solutions.
The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators and use of these novel inhibitor compounds in the treatment of disease or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
39 - Transport, packaging, storage and travel services
Goods & Services
Pharmaceuticals; Medicine; Medicinal healthcare preparations. Retailing in shops, wholesaling and retailing via global computer networks of pharmaceuticals, medicines and medicinal healthcare preparations; Merchandising; Advertising, marketing and promotional services. Distribution services; Transport; Storage of pharmaceuticals, medicines and medicinal healthcare preparations; Storage of pharmaceuticals.
49.
ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1
The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
50.
ANGPTL3 BASED VACCINE FOR THE TREATMENT OF LIVER DISEASE
in vivoin vivo. More specifically, the present invention relates to a use of a vaccines which are able to influence the angiopoietin-like 3 mediated immune response for the treatment of liver diseases such as non-alcoholic steatohepatitis and non-alcoholic fatty liver disease and hyperlipidaemia, hypercholesterolemia, or atherosclerosis including the complications lead to the cardiovascular diseases (CVD) which causes morbidity and mortality.
Present invention relates to the novel heterocyclic compounds of the general formula (I) their tautomeric forms, their stereoisomers and their pharmaceutically acceptable salts etc. The invention also relates to pharmaceutical compositions containing compounds of general formula (I) that are useful in the treatment of bacterial infection.
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Present invention relates to novel salts of saroglitazar and certain polymorphic forms of saroglitazar salts. Invention provides process for the preparation of novel salts and polymorphic forms of saroglitazar. Invention also provides novel co-precipitants or premixes of saroglitazar with pharmaceutically acceptable excipients/secondary therapeutic agent and process for the preparing same.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
C07D 207/325 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Present invention provides the method of treating polycystic ovarian syndrome using compound of formula (I) or pharmaceutically acceptable salt thereof, preferably it provides method of treating polycystic ovarian syndrome in the patient diagnosed with NAFLD. Invention also provides a pharmaceutical composition comprising compound of formula (I) for treatment of polycystic ovarian syndrome, wherein compound of formula (I) is
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1β activity is implicated.
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 319/16 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
C07D 233/54 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
C07C 311/54 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 277/22 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
55.
SAROGLITAZAR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
The present invention relates to pharmaceutical compositions containing the formula (I) for the prevention, delay of progression, or treatment of a disease or condition from hepatocellular carcinoma. The present invention further provides the composition of formula (I) useful in the prevention and treatment of hepatocellular carcinoma.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
The disclosure provides a murine monoclonal antibody capable of binding and neutralizing rabies or rabies related viruses. It also provides a cocktail of at least two monoclonal antibodies with said properties. The cocktail can neutralize the virus that is derived from species such as bats, dogs, cows, mongooses, skunks, and wolves, and thus can be useful in treating a patient that has potentially been infected. Further, the disclosure provides a combination of muring monoclonal antibody or cocktail of at least two monoclonal antibodies and anti-rabies vaccine for use in post-exposure prophylaxis (PEP) with rabies or rabies-related viruses.
Pharmaceutical composition of L-asparaginase The present invention relates to stable pharmaceutical composition of L-asparaginase. In some instances, the composition is a stable lyophilized composition of pegylated L-asparaginase. Preferably, the composition is a stable lyophilized composition of pegylated L-asparaginase free from salt. In some instances, the lyophilized composition includes one or more of a sugar, buffer and amino acid. Aspects of the invention further include method of making the compositions.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
59.
A COMPOSITION COMPRISING ANTIBODY WITH REDUCED LEVEL OF BASIC VARIANTS THEREOF
The present invention relates to a composition of an antibody, preferably pertuzumab wherein the said composition comprises reduced level of antibody variants, preferably basic variants of the antibody. More preferably, the said composition comprises no more than 1 % of antibody variants containing signal peptide residue(s). Pertuzumab is a preferred antibody according to the present invention. The present invention also provides a method of making such composition.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention relates to processes for the preparation of Filgotinib. The present invention relates to novel processes for the preparation of filgotinib. The present invention also relates to novel intermediates for the preparation of filgotinib.
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
61.
SUBSTITUTED OXAZOLIDINONES FOR THE TREATMENT OF MAMMALIAN INFECTIONS
Present invention relates to novel compound of formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable mobile software and mobile applications for mobile phones, portable media players, and handheld computers used to provide information relating to therapeutic properties of pharmaceuticals for the treatment of multiple sclerosis Printed materials, namely, pamphlets, brochures, booklets, leaflets, informational flyers, informational sheets and newsletters relating to the treatment of multiple sclerosis Providing information relating to therapeutic properties of pharmaceuticals for the treatment of multiple sclerosis; home-visit nursing care; providing health care information by telephone
63.
CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA
Present invention relates to novel compound of general formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection. The compounds of general formula (I) exhibit DprE1 enzyme inhibitory activity.
A61P 31/06 - Antibacterial agents for tuberculosis
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
64.
HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS
Present invention relates to compounds of formula (1) its enantiomers, diastereomers, racemic mixtures and their pharmaceutically acceptable salts. This invention also directed to antibacterial drug compounds that are capable of treating bacterial infection which are hard to treat with existing drug compounds.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention describes a combination of a compound from Basic Fibroblast Growth Factor (bFGF) and at least one additional therapeutic agent. The formulation is preferably in a topical form. The topical pharmaceutical composition comprises a therapeutically effective amount of the Basic Fibroblast Growth Factor (bFGF) of formula (I) and at least one additional therapeutic agent, along with at least one suitable pharmaceutically acceptable carrier, diluents, vehicle or excipient. The present application relates to use of the topical pharmaceutical composition for the treatment or prevention of a suitable disease or condition, such as Vitiligo. The invention also describes the preparation of such compositions.
The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of cancer and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), and more particularly compounds that modulate the function of IRAK4.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
67.
A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF
The present invention relates to triaminopyrimidine compound 1, or pharmaceutically acceptable salts thereof, or hydrates, or solvates, or polymorphs, or optically active forms thereof, in solid state forms. The invention also relates to a process for preparation of triaminopyrimidine compound and intermediates thereof. The present invention also relates to a pharmaceutical composition comprising pure triaminopyrimidine compound, useful for preventing or treating malaria.
C07D 213/73 - Unsubstituted amino or imino radicals
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
68.
A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF
The present invention relates to triaminopyrimidine compound 1, or pharmaceutically acceptable salts thereof, or hydrates, or solvates, or polymorphs, or optically active forms thereof, in solid state forms. The invention also relates to a process for preparation of triaminopyrimidine compound and intermediates thereof. The present invention also relates to a pharmaceutical composition comprising pure triaminopyrimidine compound, useful for preventing or treating malaria.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 213/73 - Unsubstituted amino or imino radicals
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 319/16 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
C07D 233/54 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
C07C 311/54 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 277/22 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 213/34 - Sulfur atoms to which a second hetero atom is attached
C07D 307/38 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
The present invention provides compounds which are modulators of RORϒ and their use for the treatment of diseases or conditions mediated by RORϒ. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, deuterated form, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them. formula (I)
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Novel protein drug conjugate formulation The invention provides stable pharmaceutical formulation comprising a protein drug conjugate along with one or more suitable excipient(s) such that the formulation is devoid of any buffer components and methods of making the same. The protein drug conjugate according to the present invention is antibody drug conjugate, preferably trastuzumab maytansinoid conjugate. Suitable excipient(s) according to the present invention is selected from suitable bulking agents, suitable tonicity modifiers, suitable stabilizers and the like.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
76.
STERILE INJECTABLE COMPOSITIONS COMPRISING DRUG MICELLES
The present invention relates to sterile injectable compositions comprising drug-phospholipid micelles. The present invention also relates to processes for the preparation of the sterile injectable compositions.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
77.
A PARENTERAL CONTROLLED RELEASE COMPOSITION OF AN ATYPICAL ANTIPSYCHOTIC AGENT
The present invention relates to a parenteral controlled release composition comprising one or more atypical antipsychotic or their pharmaceutically acceptable salts, one or more rate controlling polymer, optionally one or more pharmaceutically acceptable excipients. The present invention also relates to the process of preparing such compositions. Furthermore, the present invention relates to the use of said composition for the prophylaxis or treatment of psychotic disorders.
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them (Formula I).
C07D 263/56 - BenzoxazolesHydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.
C07D 263/56 - BenzoxazolesHydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 277/22 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A novel crystalline form of rifaximin and process for its preparation are described. A pharmaceutical composition comprising crystalline rifaximin is also described.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
C30B 7/02 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
B65D 30/08 - Sacks, bags or like containers characterised by the material used with laminated or multiple walls in spaced face-to-face relationship, e.g. double walls
B65D 81/26 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, fluids, e.g. exuded by contentsApplications of corrosion inhibitors or desiccators
B65B 31/00 - Packaging articles or materials under special atmospheric or gaseous conditionsAdding propellants to aerosol containers
B65B 7/02 - Closing containers or receptacles deformed by, or taking-up shape of, contents, e.g. bags, sacks
B65B 61/20 - Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for adding cards, coupons or other inserts to package contents
85.
AN INTRANASAL COMPOSITION COMPRISING 5HT1B/1D RECEPTOR AGONISTS
The present invention relates to an intranasal composition comprising 5HT1B/1D receptor agonists for treatment of cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. More particularly, the invention relates to an intranasal composition comprising at least one efflux modulator along with other pharmaceutically acceptable excipients.
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
86.
EXTENDED RELEASE OSMOTIC DOSAGE FORM COMPRISING HIGH METHYLPHENIDATE HYDROCHLORIDE LOAD
The present invention provides an extended release osmotic tablet dosage form comprising methylphenidate hydrochloride (MPH). The dosage form comprises a core tablet comprising methylphenidate hydrochloride in an amount of more than 8% by weight of the core tablet; a semipermeable membrane surrounding the core tablet, and an immediate release drug coat comprising methylphenidate hydrochloride surrounding the semipermeable membrane.
The present invention relates to the use of Saroglitazar or a pharmaceutically acceptable salt thereof, for the treatment of, or the prevention, delay of progression, or treatment of a disease or condition related with disorders of the eye. The disorders of the eye is selected from ocular inflammation, corneal inflammation, diabetic retinopathy (DR), diabetic macular edema, macular degeneration (including, but not limited to, age related macular degeneration), uveitis, retinal inflammation, retinal vascular leakage, retinal neovascularization, cancer, and other inflammatory and neovascular disorders of the eye. The present invention further relates to the use of a pharmaceutical composition comprising Saroglitazar, or a pharmaceutically acceptable salt thereof, for the prevention, delay of progression, or treatment of a disease or condition which is selected from ocular inflammation, corneal inflammation, diabetic retinopathy (DR), diabetic macular edema, macular degeneration (including, but not limited to, age related macular degeneration), uveitis, retinal inflammation, retinal vascular leakage, retinal neovascularization, cancer, and other inflammatory and neovascular disorders of the eye.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
88.
DUAL PPAR MODULATORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY AND RELATED DISEASES
The present invention relates to the use of Saroglitazar or a pharmaceutically acceptable salt thereof, for the treatment of, or the prevention, delay of progression, or treatment of a disease or condition associated with abnormalities of the diabetic Kidney. Which is selected from diabetic nephropathy, diabetic kidney disease, renal hypertrophy, hyperfiltration, nephrotic syndrome, early stage diabetic kidney disease, chronic kidney disease and associated disorders. The present invention further relates to the use of a pharmaceutical composition comprising Saroglitazar, or a pharmaceutically acceptable salt thereof, for the prevention, delay of progression, or treatment of a disease or condition which is selected from diabetic nephropathy, diabetic kidney disease, renal hypertrophy, hyperfiltration, nephrotic syndrome, early stage diabetic kidney disease, chronic kidney disease and associated disorders. Formula (1)
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
89.
PHARMACEUTICAL COMBINATION OF NK3 RECEPTOR ANTAGONIST AND BIGUANIDES
The present invention describes a synergistic composition comprising of NK3 receptor antagonist or a pharmaceutically effective salts thereof and biguanides or a pharmaceutically effective salts thereof for the treatment of PCOS and related diseases. The present invention is directed to a synergistic combination comprising combinations of a NK3 receptor antagonist or pharmaceutically effective salts thereof and biguanides or pharmaceutically effective salts thereof in a single unit pharmaceutical composition. The invention is further related to methods of preparing such pharmaceutical composition in separate in either a kit form containing both the active agents and methods of treating a subject with the same.
The present invention describes a synergistic composition comprising of Fimasartan or pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof for the treatment of cardiovascular and related disease. The present invention is directed to a synergistic combination comprising combinations of Fimasartan or suitable pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof in a single unit pharmaceutical composition. The present invention is further directed to combinations of Fimasartan or a pharmaceutically effective salt thereof and a NEP inhibitor or a pharmaceutically effective salt thereof. The invention also relates to combining separate pharmaceutical compositions of Fimasartan and a NEP inhibitor in kit form. The invention is further related to methods of preparing such pharmaceutical composition in separate in either a kit form containing both the active agents and methods of treating a subject with the same.
The present invention relates to certain polyphenol(s) having adjuvant property that can be used for the vaccine preparation. Also, the current invention provides adjuvant system comprising said polyphenol(s) and delivery system such as an immunostimulating reconstituted influenza virosomes (IRIVs). The present invention illustrates the said polyphenol(s) or an adjuvant system comprising of such polyphenol(s) and IRIVs can provide better level of immune response against antigen of interest than conventional vaccine systems. The preferred polyphenol according to the present invention can be beta-sitosterol. Beta-sitosterol can be optionally combined with the known adjuvant(s) to enhance immune response.
The present invention relates to compositions comprising saroglitazar magnesium wherein the saroglitazar magnesium has a purity of greater than or equal to 99% by weight, and dimer compound of Formula (IV) present in an amount relative to saroglitazar magnesium less than about 0.3% by weight by area percentage of HPLC. The present invention also related to the process for the preparation thereof and pharmaceutical compositions comprising the same.
C07D 207/333 - Radicals substituted by oxygen or sulfur atoms
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
The present invention relates to the treatment of psoriasis and other skin disorders. More particularly, the present invention relates to compositions for treating such disorders, the compositions comprising submicron size droplets of corticosteroids and salts or esters thereof with oily excipients. The present invention also relates to process for the preparation of such compositions.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
94.
SOLID STATE FORMS OF TRISODIUM SALT OF VALSARTAN/SACUBITRIL COMPLEX AND SACUBITRIL
The present invention describes an amorphous form of trisodium salt of valsartan sacubitril complex and a process for the preparation of same comprising: reacting sacubitril sodium and valsartan disodium or sacubitril and valsartan in the presence of a sodium ion source in one or more solvents to obtain a solution; and obtaining the trisodium salt of valsartan sacubitril complex by the removal of the solvent from the solution or by adding an anti-solvent to the solution. The crystalline form of sacubitril sodium is characterized by x-ray powder diffraction pattern having characteristic peaks expressed in terms of 2-theta at about 6.3°, 12.0°, 13.8°, 16.5°, 18.3°, 20.0° and 23.8°±0.2° (2θ).
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (κ) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said short-chain peptides, and pharmaceutical compositions containing them and their use.
The present invention relates to the use of Saroglitazar Magnesium of formula (1), for the treatment of, or the prevention, delay of progression, or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia. The present invention further relates to the use of a pharmaceutical composition comprising Saroglitazar Magnesium for the prevention, delay of progression, or treatment of a disease or condition which is selected from chylomicronemia syndrome, familial chylomicronemia syndrome and Type V hyperlipoproteinemia.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 9/00 - Medicinal preparations characterised by special physical form
B65B 7/02 - Closing containers or receptacles deformed by, or taking-up shape of, contents, e.g. bags, sacks
B65B 31/00 - Packaging articles or materials under special atmospheric or gaseous conditionsAdding propellants to aerosol containers
B65B 61/20 - Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for adding cards, coupons or other inserts to package contents
B65D 30/08 - Sacks, bags or like containers characterised by the material used with laminated or multiple walls in spaced face-to-face relationship, e.g. double walls
B65D 81/26 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, fluids, e.g. exuded by contentsApplications of corrosion inhibitors or desiccators
98.
RECOMBINANT MUMPS VIRUS JERYL LYNN 2 BASED VACCINE
The present invention provides a novel vaccine against mumps composed of highly immunogenic rMuVJL2 (recombinant mumps virus Jeryl Lynn2 based). Further, method to develop said immunogenic composition is described in the present invention. The vaccine according to the present invention is safe, cost effective, highly efficacious and stable and consistent in terms of productivity.
